title: Genetic testing in the European Union: does economic evaluation matter?
abstract: OBJECTIVE
  We review the published economic evaluation studies applied to genetic technologies in the EU to know the main diseases addressed by these studies, the ways the studies were conducted and to assess the efficiency of these new technologies. The final aim of this review was to understand the possibilities of the economic evaluations performed up to date as a tool to contribute to decision making in this area.
  
  
  METHODS
  We have reviewed a set of articles found in several databases until March 2010. Literature searches were made in the following databases: PubMed; Euronheed; Centre for Reviews and Dissemination of the University of York-Health Technology Assessment, Database of Abstracts of Reviews of Effects, NHS Economic Evaluation Database; and Scopus. The algorithm was "(screening or diagnosis) and genetic and (cost or economic) and (country EU27)". We included studies if they met the following criteria: (1) a genetic technology was analysed; (2) human DNA must be tested for; (3) the analysis was a real economic evaluation or a cost study, and (4) the articles had to be related to any EU Member State.
  
  
  RESULTS
  We initially found 3,559 papers on genetic testing but only 92 articles of economic analysis referred to a wide range of genetic diseases matched the inclusion criteria. The most studied diseases were as follows: cystic fibrosis (12), breast and ovarian cancer (8), hereditary hemochromatosis (6), Down's syndrome (7), colorectal cancer (5), familial hypercholesterolaemia (5), prostate cancer (4), and thrombophilia (4). Genetic tests were mostly used for screening purposes, and cost-effectiveness analysis is the most common type of economic study. The analysed gene technologies are deemed to be efficient for some specific population groups and screening algorithms according to the values of their cost-effectiveness ratios that were below the commonly accepted threshold of 30,000€.
  
  
  CONCLUSIONS
  Economic evaluation of genetic technologies matters but the number of published studies is still rather low as to be widely used for most of the decisions in different jurisdictions across the EU. Further, the decision bodies across EU27 are fragmented and the responsibilities are located at different levels of the decision process for what it is difficult to find out whether a given decision on genetic tests was somehow supported by the economic evaluation results.
authors: Department of Economics, University of La Rioja, La Cigüeña 60, 26004, Logroño, Spain. fernando.antonanzas@unirioja.es
authors: Fernando
authors: F
authors: Antoñanzas
authors: R
authors: R
authors: Rodríguez-Ibeas
authors: M F
authors: MF
authors: Hutter
authors: R
authors: R
authors: Lorente
authors: C
authors: C
authors: Juárez
authors: M
authors: M
authors: Pinillos
references: J Med Genet. 1995 Apr;32(4):282-3
references: 7643357
references: Community Genet. 2008;11(6):359-67
references: 18690004
references: Genet Med. 2005 Oct;7(8):519-23
references: 16247290
references: Pharmacoeconomics. 2009;27(10):861-72
references: 19803540
references: Med Decis Making. 2009 Mar-Apr;29(2):224-38
references: 19182214
references: Prog Urol. 1998 Sep;8(4):517-23
references: 9834514
references: JAMA. 2005 Apr 27;293(16):1986-94
references: 15855432
references: Int J Technol Assess Health Care. 2006 Summer;22(3):327-37
references: 16984061
references: Ann Surg. 2007 Jan;245(1):147-51
references: 17197978
references: BMJ. 2001 Aug 25;323(7310):423-5
references: 11520837
references: Lancet. 2002 Jun 1;359(9321):1919-20
references: 12057557
references: Br Med Bull. 1998;54(4):857-75
references: 10367419
references: Health Policy. 2007 Feb;80(2):340-57
references: 16678930
references: Semin Vasc Med. 2004 Feb;4(1):97-104
references: 15199439
references: Clin Genet. 1990 Apr;37(4):241-63
references: 2112433
references: Br J Cancer. 2003 Jan 13;88(1):31-5
references: 12556955
references: Health Econ. 2002 Jun;11(4):285-99
references: 12007162
references: Fertil Steril. 2004 Apr;81(4):989-95
references: 15066453
references: J Public Health Med. 2003 Mar;25(1):47-52
references: 12669918
references: BMJ. 2002 Jun 1;324(7349):1303
references: 12039822
references: Eur Heart J. 2002 Dec;23(24):1922-30
references: 12473254
references: Lancet. 2007 Apr 7;369(9568):1187-95
references: 17416263
references: Prenat Diagn. 1993 Apr;13(4):281-92
references: 8506230
references: Prostate. 1995 Jun;26(6):299-309
references: 7540297
references: Health Econ. 1997 Mar-Apr;6(2):145-59
references: 9158967
references: Am J Public Health. 1998 Apr;88(4):551-7
references: 9550991
references: J Med Genet. 1997 Sep;34(9):741-5
references: 9321760
references: J Med Screen. 1999;6(2):60-6
references: 10444721
references: BMJ. 1991 May 11;302(6785):1133-6
references: 1710520
references: J Natl Cancer Inst. 2000 Aug 16;92(16):1345-51
references: 10944557
references: J Epidemiol Community Health. 1998 Jul;52(7):459-67
references: 9799881
references: J Med Genet. 1994 Jul;31(7):545-50
references: 7525964
references: Rev Esp Cardiol. 2009 Jan;62(1):57-65
references: 19150015
references: Fam Cancer. 2004;3(1):61-7
references: 15131408
references: Br J Cancer. 1998 Jun;77(12):2199-203
references: 9649133
references: Gesundheitswesen. 2008 Jan;70(1):18-27
references: 18273760
references: Eur J Hum Genet. 2005 Jan;13(1):69-78
references: 15483651
references: Eur J Hum Genet. 2003 Dec;11 Suppl 2:S49-87
references: 14718938
references: Int J Cancer. 2004 Nov 20;112(4):647-52
references: 15382046
references: Br J Surg. 2008 Jul;95(7):868-75
references: 18457354
references: Pharmacoeconomics. 2009;27(7):561-70
references: 19663527
references: Contraception. 1999 May;59(5):293-9
references: 10494482
references: Clin Cancer Res. 2001 Aug;7(8):2357-62
references: 11489813
references: Am J Hum Genet. 1997 May;60(5):1222-32
references: 9150170
references: Pharmacoeconomics. 2008;26(7):569-87
references: 18563949
references: Prenat Diagn. 2005 Dec;25(13):1206-11
references: 16353286
references: QJM. 2001 Jul;94(7):365-72
references: 11435632
references: Community Genet. 2008;11(2):75-120
references: 18204250
references: Bull Cancer. 2001 Nov;88(11):1119-27
references: 11741806
references: Eur J Public Health. 2001 Dec;11(4):373-9
references: 11766476
references: Eur J Hum Genet. 2002 Oct;10(10):599-606
references: 12357330
references: BMC Med Genet. 2007 Jul 02;8:42
references: 17605803
references: J Hepatol. 2005 Jul;43(1):149-55
references: 15876471
references: BMJ. 1995 Dec 2;311(7018):1460-3; discussion 1463-4
references: 8520332
references: J Community Genet. 2010 Mar;1(1):29-35
references: 22422358
references: Gut. 2005 Jan;54(1):97-102
references: 15591512
references: Cost Eff Resour Alloc. 2005 Aug 09;3:8
references: 16091139
references: QJM. 2008 Aug;101(8):631-41
references: 18522976
references: Genet Test. 2005 Summer;9(2):158-66
references: 15943557